Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AQST Aquestive Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AQST
Price (delayed)
$3.4
Market cap
$337.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$393.53M
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan,
Highlights
Aquestive Therapeutics's gross margin has increased by 14% YoY
Aquestive Therapeutics's quick ratio has decreased by 25% YoY but it has increased by 3.3% QoQ
The company's gross profit rose by 20% YoY but it fell by 7% QoQ
AQST's net income has dropped by 89% year-on-year and by 23% since the previous quarter
AQST's equity has dropped by 68% year-on-year
Key stats
What are the main financial stats of AQST
Market
Valuations
Earnings
Shares outstanding
99.33M
Market cap
$337.71M
Enterprise value
$393.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.26
Revenue
$54.23M
Gross profit
$37.09M
Operating income
-$41.18M
Net income
-$54.24M
EBIT
-$37.36M
EBITDA
-$36.71M
Free cash flow
-$49.04M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.59
Free cash flow per share
-$0.51
Book value per share
-$0.62
Revenue per share
$0.57
TBVPS
$1.07
Total assets
$102.23M
Total liabilities
$163.16M
Debt
$124.47M
Equity
-$60.93M
Working capital
$70.87M
Debt to equity
-2.04
Current ratio
4.87
Quick ratio
4.32
Net debt/EBITDA
-1.52
Margins
Efficiency
Dividend
EBITDA margin
-67.7%
Gross margin
68.4%
Net margin
-100%
Operating margin
-75.9%
Return on assets
-50.3%
Return on equity
N/A
Return on invested capital
-27.7%
Return on capital employed
-44.5%
Return on sales
-68.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AQST stock price
How has the Aquestive Therapeutics stock price performed over time
Intraday
2.72%
1 week
5.92%
1 month
25.46%
1 year
38.78%
YTD
-4.49%
QTD
2.72%
Financial performance
How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$54.23M
Gross profit
$37.09M
Operating income
-$41.18M
Net income
-$54.24M
Gross margin
68.4%
Net margin
-100%
The operating income has plunged by 112% YoY and by 34% from the previous quarter
Aquestive Therapeutics's operating margin has shrunk by 101% YoY and by 42% QoQ
AQST's net income has dropped by 89% year-on-year and by 23% since the previous quarter
The net margin has plunged by 79% YoY and by 30% from the previous quarter
Price vs fundamentals
How does AQST's price correlate with its fundamentals
Growth
What is Aquestive Therapeutics's growth rate over time
Valuation
What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.26
The EPS has declined by 37% year-on-year and by 16% since the previous quarter
AQST's equity has dropped by 68% year-on-year
AQST's P/S is 77% above its 5-year quarterly average of 3.3 and 4.1% above its last 4 quarters average of 5.6
Aquestive Therapeutics's revenue has decreased by 6% from the previous quarter but it has increased by 5% YoY
Efficiency
How efficient is Aquestive Therapeutics business performance
The return on sales has dropped by 94% year-on-year and by 45% since the previous quarter
The company's return on invested capital has shrunk by 81% YoY and by 34% QoQ
AQST's ROA is down by 33% year-on-year and by 31% since the previous quarter
Dividends
What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AQST.
Financial health
How did Aquestive Therapeutics financials performed over time
The company's total assets is 37% lower than its total liabilities
Aquestive Therapeutics's quick ratio has decreased by 25% YoY but it has increased by 3.3% QoQ
The current ratio has declined by 22% year-on-year but it has increased by 4.1% since the previous quarter
AQST's equity has dropped by 68% year-on-year
AQST's debt to equity is up by 36% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.